A Phase I/II Study of IMMU-132 (hRS7-SN38 Antibody Drug Conjugate) in Patients with Epithelial Cancer
Clinical Trial Information
Trial Contact: Morales, Leticia; Pelley, Jennifer; Walton, Sherri; Jobson, Gillian S
IRB No: 13.029.03
Protocol Abbrev: IMMU-132-01
Principal Investigator: Rebecca L. Moroose, MD
Sub Investigators: Hajdenberg, Julio MD; Johnson, Tirrell MD; Kayaleh, Omar MD; Landau, Daniel MD; Moroose, Rebecca MD; Rostorfer, Regan MD; Shah, Nikita MD; Tseng, Jennifer MD; Cuesta, Ana MD; Maddipatla, Sreeram MD
Phase: Drug: Phase I
Age Group: Adult
Secondary Protocol No: IMMU-132-01
Applicable Disease Sites: Multiple
Therapies Involved: Drug: IMMU-132
ClinicalTrials.gov ID: NCT01631552
The objective is to evaluate the safety and tolerability of IMMU-132 in previously treated patients with advanced epithelial cancer.
Must have measurable disease.